• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Risk-to-Price Commentary: Bayer AG Jun 11 Product Image

Risk-to-Price Commentary: Bayer AG Jun 11

  • Published: June 2011
  • Standard & Poors

Abstract
Following the completion of the first-quarter earnings reporting season, the Valuation and Risk Strategies (VRS) research team looked at the S&P Europe 350 Index and found that the health care sector was among the top three performing sectors relative to analyst consensus expectations recorded by Capital IQ. The sector beat consensus earnings estimates by 75%, compared with the 56% positive surprise that the S&P 350 Europe Index posted overall. The VRS Research team summarizes expected first-quarter earnings only for the S&P Europe 350 Index companies that actually report earnings on a quarterly basis. In terms of equity performance, the health care sector has caught up with the S&P Europe 350 over the last few months, with a 37% one-year return,...

Companies mentioned in this report are: Bristol-Myers Squibb Co.,Pfizer Inc.,Bayer AG,GlaxoSmithKline Capital PLC,Roche Finance Europe B.V.,Merck Financial Services GmbH,Cegedim S.A.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress READ MORE >

Bristol-Myers Squibb Co.,Pfizer Inc.,Bayer AG,GlaxoSmithKline Capital PLC,Roche Finance Europe B.V.,Merck Financial Services GmbH,Cegedim S.A.

Format Properties
Electronic The report will be emailed to you.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS